Skip to main content
. 2016 Feb 18;48(4):1338–1350. doi: 10.4143/crt.2015.430

Table 1.

Impact of baseline characteristics on patient prognosis

Variable Total (n=174), n (%) 5Y DRFS (%) p-value
Age (yr)
 Median 46.0±10.1 -
 Range 23.5-73.1 - 0.469
 < 40 46 (26.4) 80.1
 ≥ 40 128 (73.6) 86.6
Histology
 IDC 154 (88.5) 85.6 0.288
 Other 20 (11.5) 80.0
Stage
 I 44 (25.3) 88.4 < 0.001
 IIA 87 (50.0) 91.9
 IIB 25 (14.4) 75.8
 IIIA 12 (6.9) 64.8
 IIIB 0 NA
 IIIC 6 (3.4) 33.3
Nuclear grade
 1 2 (1.1) 50.0 0.144
 2 41 (23.6) 82.7
 3 125 (71.8) 87.1
 Unknown 6 (3.4) 66.7
Histologic grade
 1 3 (1.7) 100.0 0.606
 2 39 (22.4) 84.5
 3 122 (70.1) 85.9
 Unknown 10 (5.7) 70.0
p53 IHC
 Positive 103 (59.0) 85.4 0.151
 Negative 69 (40.0) 81.2
 Unknown 2 (1.1) 50.0
TP53 mutation
 Wild type 97 (55.7) 82.5 0.625
 Missense 49 (28.2) 81.6
 Nonsense/Frameshift/Splicing 28 (16.1) 89.3
TP53 mRNA expression
 Median 228.52±147.81 - 0.593
 Range 32.40-736.09 -
 Low 87 (50.0) 81.6
 High 87 (50.0) 85.1
Adjuvant CTx
 CMF 76 (43.7) 89.4 0.001
 Anthracycline 63 (36.2) 90.3
 Anthracycline+taxane 35 (20.1) 65.5
Adjuvant RTx
 Yes 110 (63.2) 82.5 0.109
 No 64 (36.8) 89.0

5Y DRFS, 5-year distant recurrence-free survival; IDC, invasive ductal carcinoma; IHC, immunohistochemistry; CTx, chemotherapy; CMF, cyclophosphamide+methotrexate+5-fluorouracil; RTx, radiotherapy.